It was firstly approved by USA FDA as an agent to treat tumors of gastrointestinal tract endocrine and hypophysis and acromegaly in 1988, then approved byUSA FDA to treat acromegaly in 1998 again.

• 其于1988 年首次在美国上市，主要用于胃肠道分泌类肿瘤和垂体肿瘤及肢端肥大症的治疗，1998 年美国FDA 再次批准醋酸奥曲肽用于肢端肥大症的治疗。